FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988642006> ?p ?o ?g. }

• W2988642006 endingPage "141" @default.
• W2988642006 startingPage "132" @default.
• W2988642006 abstract "•Among interventional ophthalmology trials registered on Clinical Trials.gov between October 1, 2007, and May 1, 2018, most were funded by industry, with less than 5% funded by the National Institutes of Health. •Industry-funded ophthalmology trials were more likely to be larger, multiarmed, multicentered, double-blinded, and/or randomized but least likely to use a data-monitoring committee. •Ophthalmology trials vary significantly in methodological approach, warranting discussions regarding study design, disease focus, and funding allocation. Purpose To perform a comprehensive analysis of characteristics of ophthalmology trials registered in ClinicalTrials.gov. Design Cross-sectional study. Methods All 4,203 ophthalmologic clinical trials registered on ClinicalTrials.gov between October 1, 2007, and April 30, 2018, were identified by using medical subject headings (MeSH). Disease condition terms were verified by manual review. Trial characteristics were assessed through frequency calculations. Hazard ratios and 95% confidence intervals were determined for characteristics associated with early discontinuation. Results The majority of trials were multiarmed (73.6%), single-site (69.4%), randomized (64.8%), and had <100 enrollees (66.3%). A total of 33% used a data-monitoring committee (DMC), and 50.6% incorporated blinding. Other groups (51.6%) were funded by industry, whereas 2.6% were funded by the US National Institutes of Health (NIH). NIH trials were significantly more likely to address oncologic (NIH = 15.5%, Other = 3%, Industry = 1.5%; P < 0.001) or pediatric disease (NIH = 20.9%, Other = 5.9%, Industry = 1.4%; P < 0.001). Industry-sponsored trials (69.6% of phase 3 trials) were significantly more likely to be randomized (Industry = 68.7%, NIH = 58.9%, Other = 60.8%; P < 0.001) and blinded (Industry = 57.2%, NIH = 42.7%, Other = 43.5%; P < 0.001). A total of 359 trials (8.5%) were discontinued early, and 530 trials (12.6%) had unknown status. Trials were less likely to be discontinued if funded by sources other than industry (hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.55-0.95; P = 0.021) and/or had a DMC (HR, 0.71; 95% CI, 0.55-0.92; P = 0.010). Conclusions Ophthalmology trials in the past decade reveal heterogeneity across study funding sources. NIH trials were more likely to support historically underfunded subspecialties, whereas Industry trials were more likely to face early discontinuation. These trends emphasize the importance of carefully monitored and methodologically sound trials with deliberate funding allocation. To perform a comprehensive analysis of characteristics of ophthalmology trials registered in ClinicalTrials.gov. Cross-sectional study. All 4,203 ophthalmologic clinical trials registered on ClinicalTrials.gov between October 1, 2007, and April 30, 2018, were identified by using medical subject headings (MeSH). Disease condition terms were verified by manual review. Trial characteristics were assessed through frequency calculations. Hazard ratios and 95% confidence intervals were determined for characteristics associated with early discontinuation. The majority of trials were multiarmed (73.6%), single-site (69.4%), randomized (64.8%), and had <100 enrollees (66.3%). A total of 33% used a data-monitoring committee (DMC), and 50.6% incorporated blinding. Other groups (51.6%) were funded by industry, whereas 2.6% were funded by the US National Institutes of Health (NIH). NIH trials were significantly more likely to address oncologic (NIH = 15.5%, Other = 3%, Industry = 1.5%; P < 0.001) or pediatric disease (NIH = 20.9%, Other = 5.9%, Industry = 1.4%; P < 0.001). Industry-sponsored trials (69.6% of phase 3 trials) were significantly more likely to be randomized (Industry = 68.7%, NIH = 58.9%, Other = 60.8%; P < 0.001) and blinded (Industry = 57.2%, NIH = 42.7%, Other = 43.5%; P < 0.001). A total of 359 trials (8.5%) were discontinued early, and 530 trials (12.6%) had unknown status. Trials were less likely to be discontinued if funded by sources other than industry (hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.55-0.95; P = 0.021) and/or had a DMC (HR, 0.71; 95% CI, 0.55-0.92; P = 0.010). Ophthalmology trials in the past decade reveal heterogeneity across study funding sources. NIH trials were more likely to support historically underfunded subspecialties, whereas Industry trials were more likely to face early discontinuation. These trends emphasize the importance of carefully monitored and methodologically sound trials with deliberate funding allocation." @default.
• W2988642006 created "2019-11-22" @default.
• W2988642006 creator A5008708150 @default.
• W2988642006 creator A5012792821 @default.
• W2988642006 creator A5021200670 @default.
• W2988642006 creator A5081308768 @default.
• W2988642006 creator A5083327006 @default.
• W2988642006 creator A5084218184 @default.
• W2988642006 creator A5085491819 @default.
• W2988642006 creator A5089344187 @default.
• W2988642006 date "2020-03-01" @default.
• W2988642006 modified "2023-09-24" @default.
• W2988642006 title "Characteristics of Ophthalmology Trials Registered in ClinicalTrials.gov, 2007-2018" @default.
• W2988642006 cites W1534550218 @default.
• W2988642006 cites W1597439812 @default.
• W2988642006 cites W1970394039 @default.
• W2988642006 cites W1976050365 @default.
• W2988642006 cites W1977025521 @default.
• W2988642006 cites W1993595811 @default.
• W2988642006 cites W1997362383 @default.
• W2988642006 cites W2000248401 @default.
• W2988642006 cites W2016526647 @default.
• W2988642006 cites W2017857169 @default.
• W2988642006 cites W2023903257 @default.
• W2988642006 cites W2030320337 @default.
• W2988642006 cites W2035935210 @default.
• W2988642006 cites W2055882248 @default.
• W2988642006 cites W2055932832 @default.
• W2988642006 cites W2076751598 @default.
• W2988642006 cites W2077980817 @default.
• W2988642006 cites W2079796774 @default.
• W2988642006 cites W2080773973 @default.
• W2988642006 cites W2083258699 @default.
• W2988642006 cites W2087351488 @default.
• W2988642006 cites W2092025391 @default.
• W2988642006 cites W2093728178 @default.
• W2988642006 cites W2128542677 @default.
• W2988642006 cites W2128681611 @default.
• W2988642006 cites W2134216627 @default.
• W2988642006 cites W2134370756 @default.
• W2988642006 cites W2170489475 @default.
• W2988642006 cites W2213629364 @default.
• W2988642006 cites W2268543367 @default.
• W2988642006 cites W2413356836 @default.
• W2988642006 cites W2490038287 @default.
• W2988642006 cites W273139479 @default.
• W2988642006 cites W2804642607 @default.
• W2988642006 cites W2068907270 @default.
• W2988642006 doi "https://doi.org/10.1016/j.ajo.2019.11.004" @default.
• W2988642006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31730839" @default.
• W2988642006 hasPublicationYear "2020" @default.
• W2988642006 type Work @default.
• W2988642006 sameAs 2988642006 @default.
• W2988642006 citedByCount "21" @default.
• W2988642006 countsByYear W29886420062020 @default.
• W2988642006 countsByYear W29886420062021 @default.
• W2988642006 countsByYear W29886420062022 @default.
• W2988642006 countsByYear W29886420062023 @default.
• W2988642006 crossrefType "journal-article" @default.
• W2988642006 hasAuthorship W2988642006A5008708150 @default.
• W2988642006 hasAuthorship W2988642006A5012792821 @default.
• W2988642006 hasAuthorship W2988642006A5021200670 @default.
• W2988642006 hasAuthorship W2988642006A5081308768 @default.
• W2988642006 hasAuthorship W2988642006A5083327006 @default.
• W2988642006 hasAuthorship W2988642006A5084218184 @default.
• W2988642006 hasAuthorship W2988642006A5085491819 @default.
• W2988642006 hasAuthorship W2988642006A5089344187 @default.
• W2988642006 hasConcept C118487528 @default.
• W2988642006 hasConcept C126322002 @default.
• W2988642006 hasConcept C168563851 @default.
• W2988642006 hasConcept C207103383 @default.
• W2988642006 hasConcept C2771230 @default.
• W2988642006 hasConcept C2778715236 @default.
• W2988642006 hasConcept C44249647 @default.
• W2988642006 hasConcept C512399662 @default.
• W2988642006 hasConcept C535046627 @default.
• W2988642006 hasConcept C71924100 @default.
• W2988642006 hasConceptScore W2988642006C118487528 @default.
• W2988642006 hasConceptScore W2988642006C126322002 @default.
• W2988642006 hasConceptScore W2988642006C168563851 @default.
• W2988642006 hasConceptScore W2988642006C207103383 @default.
• W2988642006 hasConceptScore W2988642006C2771230 @default.
• W2988642006 hasConceptScore W2988642006C2778715236 @default.
• W2988642006 hasConceptScore W2988642006C44249647 @default.
• W2988642006 hasConceptScore W2988642006C512399662 @default.
• W2988642006 hasConceptScore W2988642006C535046627 @default.
• W2988642006 hasConceptScore W2988642006C71924100 @default.
• W2988642006 hasFunder F4320306811 @default.
• W2988642006 hasFunder F4320337337 @default.
• W2988642006 hasFunder F4320337350 @default.
• W2988642006 hasLocation W29886420061 @default.
• W2988642006 hasLocation W29886420062 @default.
• W2988642006 hasOpenAccess W2988642006 @default.
• W2988642006 hasPrimaryLocation W29886420061 @default.
• W2988642006 hasRelatedWork W2039052235 @default.
• W2988642006 hasRelatedWork W2041814125 @default.
• W2988642006 hasRelatedWork W2466043692 @default.
• W2988642006 hasRelatedWork W2598191995 @default.

• next